Our previous studies suggest that this is through a mechanism by which hepatic FGF21 targets extra-hepatic adipocytes and adipose tissues via an endocrine mechanism for compensatory metabolic regulation and alleviation of metabolic diseases including fatty liver, obesity and diabetes [5,6,8-10]. The gene discussed is FGF21; the disease is Hepatic steatosis.